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Silver nanoparticle (Ag NP)/chitosan (Ch) composites with antiviral activity against H1N1 influenza A virus were
prepared. The Ag NP/Ch composites were obtained as yellow or brown floc-like powders following reaction at
room temperature in aqueous medium. Ag NPs (3.5, 6.5, and 12.9 nm average diameters) were embedded into the
chitosan matrix without aggregation or size alternation. The antiviral activity of the Ag NP/Ch composites was
evaluated by comparing the TCID50 ratio of viral suspensions treated with the composites to untreated suspensions.
For all sizes of Ag NPs tested, antiviral activity against H1N1 influenza A virus increased as the concentration of Ag
NPs increased; chitosan alone exhibited no antiviral activity. Size dependence of the Ag NPs on antiviral activity was
also observed: antiviral activity was generally stronger with smaller Ag NPs in the composites. These results indicate
that Ag NP/Ch composites interacting with viruses exhibit antiviral activity.
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Silver nanoparticles (Ag NPs) are well-known antimicro-
bial materials effective against many types of bacteria [1-3]
and fungi [4]. The antibacterial and antifungal activities of
Ag NPs are mainly due to the inhibition of respiratory
enzymes by released Ag+ ions [1,5]. Recently, the anti-
microbial activities of Ag NPs against viruses such as HIV-
1 [6,7], hepatitis B [8], herpes simplex [9], respiratory
syncytial [10], monkeypox [11], Tacaribe [12], and H1N1
influenza A virus [13,14] have also been investigated. Un-
like its antibacterial and antifungal activities, the major
antiviral mechanism of Ag NPs is likely the physical inhib-
ition of binding between the virus and host cell. A de-
pendence of the size of Ag NPs on antiviral activity was
observed for the viruses mentioned above; for example,
Ag NPs smaller than 10 nm specifically inhibited infection
by HIV-1 [6]. This property of Ag NPs holds promise that
antimicrobial materials based on Ag NPs will be effective
against many types of bacteria, fungi, and viruses.
On the other hand, there are some concerns about the
biological and environmental risks of Ag NPs. It is known
that Ag NPs have adverse effects, such as cytotoxicity and* Correspondence: ishihara@ndmc.ac.jp
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in any medium, provided the original work is pgenotoxicity on aquatic organisms like fish [15], and
can inhibit photosynthesis in algae [16]. One study on
mammals showed a significant decline in mouse sperm-
atogonial stem cells following the administration of Ag
NPs [17]. Therefore, preventing the diffusion and intake of
Ag NPs into the environment and the biosphere are im-
portant considerations in the design of antimicrobial
materials containing Ag NPs [18-22]. One approach would
be the fixation of Ag NPs into matrices; for example, Fayaz
et al. have prepared Ag NP-coated polyurethane and
have demonstrated its antiviral activity against HIV-1
and herpes simplex virus [23]. Nevertheless, the efficacy
and mechanism of action of such Ag NP-fixed anti-
viral materials against various viral strains are not well
investigated.
In this paper, the antiviral activity of Ag NP/polymer
composites against H1N1 influenza A virus was inves-
tigated. Chitosan (Ch), which is the main constituent of
the exoskeleton of crustaceans and exhibits strong anti-
bacterial activity [24], was used as the matrix polymer.
Controlling the size of Ag NPs is as important to anti-
viral activity as the composition of the Ag NPs. We
previously demonstrated an environmentally friendly
process for producing Ag NPs with a narrow size distri-
bution [25]. This process uses only three materials:
a silver-containing glass powder as an Ag+ supplier,Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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ent. The stabilizing agent for Ag NPs is caramel, which
is generated from glucose during heating to reduce Ag+.
In this work, Ag NPs synthesized by this process were
used to make the Ag NP/Ch composites, since the size
of the Ag NPs could be easily controlled without the
use or production of hazardous materials. Ag NP/Ch
composites were synthesized in aqueous media at room
temperature by mixing a chitosan solution and an Ag
NP suspension. The surface and internal structure of
the synthesized Ag NP/Ch composites were observed by
scanning and transmission electron microscopies, re-
spectively. The effect of introducing a small amount of
Ag NPs into the chitosan matrices and the effect of the
size of the Ag NPs were evaluated with respect to the
antiviral activity of the composites.
Methods
Materials
Ag NP suspensions were synthesized from silver-
containing glass powder (BSP21, silver content 1 wt%,
average grain size 10 μm, Kankyo Science, Kyoto, Japan)
and glucose aqueous solution, as described previously
[25]. Ag NPs used in this work were spherical; their
characteristics are summarized in Table 1. Phosphate-
buffered saline (PBS), methanol, Giemsa stain solution,
and 5 M hydrochloric acid (HCl) and 5 M sodium hy-
droxide (NaOH) aqueous solutions were purchased from
Wako Pure Chemical Industries, Ltd. (Osaka, Japan) and
used without further purification. Chitosan solution (10
mg/mL) was prepared by mixing 0.1 g chitosan (average
molecular weight 54 kg/mol, deacetylation ratio 84%;
Yaizu Suisankagaku Industry Co., Ltd., Shizuoka, Japan),
10 mL of PBS, and 100 μL of 5 M HCl; following
complete dissolution of the chitosan, the solution was
filter-sterilized by passage through a 0.2-μm filter. Bovine
serum albumin (BSA) solution was prepared using BSA
powder (Sigma-Aldrich Japan, Tokyo, Japan) and PBS,
then filter-sterilized as above. Trypsin was obtained from
Life Technologies Co., (Carlsbad, CA, USA). Dulbecco's
Modified Eagle Medium (DMEM, high glucose) was
purchased from Sigma-Aldrich Japan (Tokyo, Japan).
Synthesis of Ag NP/Ch composites
Chitosan solution (100 μL, 10 mg/mL) was mixed with





Concentration of Ag NP in
suspension (μg/mL)
SN35 3.5 ± 1.8 73
SN65 6.5 ± 1.8 62
SN129 12.9 ± 2.5 77at room temperature, followed by vigorous stirring to
precipitate the Ag NP/Ch composite. The obtained Ag
NP/Ch composite was centrifuged at 6,000 rpm for 10
min. The supernatant was analyzed using a UV-visible
spectrometer (JASCO V-630, Tokyo, Japan) to estimate
the amount of unreacted Ag NPs. Centrifuged com-
posites were washed with 1 mL PBS, followed by centri-
fugation at 6,000 rpm for 10 min. The washing process
was repeated twice. The washed Ag NP/Ch composite
was suspended in 250 μL PBS and used in antiviral
assays the same day. Synthesis of the Ag NP/Ch
composites was carried out in a laminar flow cabinet to
prevent biological contamination.Microscopy observations
Scanning electron microscopy (SEM) specimens of the
composites were prepared by casting 5 μL of a water
dispersion of the Ag NP/Ch composite, followed by
drying at room temperature. Osmium plasma coating
was conducted to enhance the conductivity of the
specimens. Dried samples were coated using a plasma
multi-coater PMC-5000 (Meiwafosis Co., Ltd., Tokyo,
Japan). SEM observation was performed using a JSM-
6340F (JEOL, Tokyo, Japan) at 5 kV. Transmission
electron microscopy (TEM) specimens of the Ag NPs
and Ag NP composites were prepared by casting 5 μL
of Ag NP solution or a water dispersion of the compos-
ite onto a carbon-coated copper microgrid. Excess so-
lution was removed using filter paper, and the
specimens were dried at room temperature. Further
staining was not carried out for any specimen. TEM
observation was performed using a JEM-1010 (JEOL)
at 80 kV.Figure 1 A SEM micrograph of chitosan/SN129. Weight ratio of


















Figure 2 UV-visible spectra of the original Ag NP suspension
and of the post-reaction mixture supernatant. Solid line and
dashed line correspond to the original Ag NP suspension and the
post-reaction mixture supernatant, respectively. (a) SN35 and the
supernatants obtained from 1 mg of chitosan and 328.5 μg of SN35,
(b) SN65 and the supernatants obtained from 1 mg of chitosan and
279 g μof SN65, (c) SN129 and the supernatants obtained from 1
mg of chitosan and 308 μg of SN129. The peak due to Ag NPs is
marked with a vertical line. The supernatants were obtained from
the post-reaction mixture of 1 mg of chitosan and 328.5 μg of SN35
(dotted line), 279 μg of SN65 (short dashed line), and 308 μg of
SN129 (long dashed line). The solid line corresponds to the original
suspension of SN129.
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composites
Human influenza A virus (A/PR/8/34 (H1N1)), obtained
from Life Technologies Co., was used and assayed using
the fifty-percent tissue culture infectious dose (TCID50)
method. Viral suspension in PBS (250 μL, titer ca. 1,000
TCID50/mL) was added to 250 μL Ag NP/Ch composite
suspension. The mixture was stirred vigorously for 5 s
and then left at room temperature for 1 h to allow the
virus and composite particles to interact. Then, the mix-
ture was centrifuged at 6,000 rpm for 10 min to remove
the composite particles. The supernatant (50 μL) was
subjected to two-fold serial dilution with PBS 11 times
in a 96-well cell culture plate sown with Madin-Darby
canine kidney (MDCK) cells. Eight duplicate dilution
series were prepared and assayed for each Ag NP/Ch
sample. Samples were incubated at 37C and 5% CO2
for 1 h to allow viral infection of the MDCK cells.
MDCK cells were maintained by adding 50 μL DMEM
(with the addition of 0.4% of BSA and 5 ppm of trypsin)
to each well immediately following infection and again 5
days post-infection. Seven days post-infection, the living
cells were fixed with methanol and stained with 5%
Giemsa stain solution. The TCID50 of the sample solu-
tion was calculated from the number of infected wells
using the Reed-Muench method [26,27]. The antiviral
activity of the Ag NP/Ch composite was estimated as
the TCID50 ratio of the Ag NP/Ch-treated supernatant
to the control (untreated) viral suspension.
Results and discussion
Ag NP/Ch composites were synthesized by mixing a
chitosan acidic aqueous solution with an Ag NP suspen-
sion. Chitosan is water soluble in acidic conditions due
to protonation of primary amines in the chitosan chains.
The Ag NP suspension was also acidic (pH 5.23 to 6.25)
[25]. Although the acidity of these two solutions was
maintained during mixing, partial precipitation of the
Ag NP/Ch composites was observed at all conditions
tested, suggesting that decreased solubility of the
chitosan chains was induced by the binding of Ag
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Addition of excess NaOH completely precipitated the
composite. Figure 1 shows a typical SEM micrograph of
the composite. Ag NP/Ch composites were obtained as
flocculated, aggregated, spherical sub-micrometer par-
ticles. The composites were yellow or brown; darker
composites were obtained when larger amounts of Ag
NPs were reacted with the chitosan. Figure 2 shows UV-
visible spectra of the original Ag NP suspension and of
the reaction mixes containing high amounts of Ag NP.
Since spherical Ag NPs provide a peak near 400 nm
[25,29], the absence of this peak shows that Ag NPs are(a)
(b)
(c)
Figure 3 TEM micrographs of Ag NPs. (a) SN35, (b) SN65, (c) SN129; Ag
(f) 23.5 wt% of SN129.not present in the supernatant of the post-reaction mix-
ture and that the Ag NPs were completely bound to the
chitosan.
TEM micrographs of the Ag NPs and Ag NP/Ch
composites are shown in Figure 3. Compared to Ag NPs
before reaction, Ag NPs in the composites are dispersed in
the chitosan matrix and appear as uneven gray domains.
The thickness of the TEM specimen of the composites is
uneven due to the direct casting of the composite floc.
Uneven contrast of the chitosan domains is due to the un-
even thickness of the specimen. Ag NPs in thick areas of




NP/Ch composites (d) 24.7 wt% of SN35, (e) 21.8 wt% of SN65,
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Ag NPs in the composites are similar to that of the ori-
ginal Ag NPs. Although some minor aggregation of Ag
NPs was observed, there was no macroscopic aggregation,
showing that the particle size of the Ag NPs in the Ag NP/
Ch composites was controlled.
Figure 4 shows the dependence of particle size and
amount of Ag NPs on the antiviral activity of the
composites against influenza A virus. The TCID50 ratios
of viral suspensions treated with Ag NPs and Ag NP/Ch
composites to untreated suspensions were used to gauge
the antiviral activity of the materials. For all Ag NPs
tested, the antiviral activity of the Ag NP/Ch composites
increased with increasing amount of Ag NPs. No anti-
viral activity was observed with chitosan alone, showing
that the antiviral activity of the composites was due to
the bound Ag NPs. The effect of size of the Ag NPs in
the composites was also observed: for similar con-
centrations of Ag NPs, stronger antiviral activity was
generally observed with composites containing smaller
Ag NPs. This size effect was most prominent when less
than 100 μg of Ag NPs was added to 1 mg of chitosan.
No increase in antiviral activity was observed above 200
μg of Ag NPs per 1 mg of chitosan, irrespective of the
size of the Ag NPs.
Previous studies showed that Ag NPs have antiviral ac-
tivity against influenza A virus [13,14]. Although the
mechanism of action has not been well investigated, it is
likely that the antiviral activity of Ag NPs against several
other types of viruses is due to direct binding of the Ag
NPs to viral envelope glycoproteins, thereby inhibiting
viral penetration into the host cell [6,8,13,30]. The effect


































Amount of AgNPs per 1 mg of chitosan [µg]
Figure 4 Relationship between the anti-influenza virus activity
of Ag NP/Ch composites and their composition. SN35 (square),
SN65 (diamond), and SN129 (circle).observed, suggesting spatial restriction of binding be-
tween virions and Ag NPs [6,8]. For the Ag NP/Ch
composites, further spatial restriction due to the chi-
tosan matrix would be expected to prevent or weaken
the interaction between virions and Ag NPs. On the
other hand, physical binding of virions to the composites
could directly inhibit viral contact with host cells since
the virus-treated composites were removed from the
assay solution prior to infection of the host cells. When
embedded Ag NPs could interact with the virions, the
interaction between the virions and the composites
should increase with increased concentration of Ag NPs
in the composites; this is supported by the experimental
results on the relationship between the antiviral activity
and the concentration of Ag NPs. The effect of the size
of Ag NPs in the composites on antiviral activity
suggests that influenza A virus interacted selectively with
smaller Ag NPs, as previously reported for other types of
viruses [6,8]. However, the size dependence of free Ag
NPs on antiviral activity against influenza A virus has
not been studied. To obtain more effective Ag NP-
embedded antiviral materials, detailed studies of the
mechanism of antiviral action of both free and embed-
ded Ag NPs are required. The effects of the microscopic
structure and the properties of Ag NP-embedded ma-
terials on antiviral activity should also be investigated in
the future. Nonetheless, this study clearly demon-
strates the feasibility of using Ag NPs to impart antiviral
activity to chitosan and lower concerns about the risk of
diffusion of Ag NPs in the environment.
Conclusions
Ag NP/Ch composites with antiviral activity against in-
fluenza A virus were synthesized in aqueous medium.
The composites were obtained as yellow or brown flocs;
unreacted Ag NPs were not detected in the residual so-
lution. The particle size of the Ag NPs in the composites
was similar to that of the Ag NPs used to synthesize the
composites. The antiviral activity of the composites was
determined from the decreased TCID50 ratio of viral
suspensions after treatment with the composites. For all
sizes of Ag NPs tested, the antiviral activity of the Ag
NP/Ch composites increased as the amount of Ag NPs
increased. Stronger antiviral activity was generally ob-
served with composites containing smaller Ag NPs for
comparable concentrations of Ag NPs. Neat chitosan did
not exhibit antiviral activity, suggesting that Ag NPs are
essential for the antiviral activity of the composites.
Although the antiviral mechanism of the composites
remains to be investigated, the experimental results
showing the relationship between antiviral activity and the
concentration of Ag NPs suggest that the virions and
composites interacted. Consequently, detailed studies of
the antiviral mechanism of the Ag NP/Ch composites
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containing materials that will reduce concerns about the
risks of diffusion of Ag NPs into the environment.
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